Prolia (Denosumab) Cost in Virginia 2026: Prices, Insurance, and Savings

What Does Prolia (Denosumab) Cost Without Insurance in Virginia?

The average cash price for a single 60 mg prefilled syringe of Prolia across Virginia retail pharmacies sits near $1,500 in 2026. That translates to roughly $3,000 per year for the standard every-six-months dosing schedule. Prices vary by pharmacy location, and some independent pharmacies in northern Virginia or the Tidewater region may charge slightly more or less than chain outlets.

Denosumab is a RANK ligand inhibitor that prevents osteoclast formation, reducing bone resorption and increasing bone mineral density. The FREEDOM trial (N=7,868) demonstrated that 60 mg denosumab administered subcutaneously every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared to placebo over 36 months [1]. Those results established denosumab as a first-line option for postmenopausal osteoporosis when bisphosphonates are contraindicated or not tolerated.

The $1,500-per-dose figure reflects Amgen's wholesale acquisition cost (WAC). Retail markups, dispensing fees, and regional cost-of-living differences mean Virginia patients without coverage should request quotes from at least two or three pharmacies before filling. Some specialty pharmacies operating in Virginia offer modest discounts on biologic medications when patients pay cash.

Because Prolia is a provider-administered injectable (given in a physician's office or infusion center), the total out-of-pocket bill for uninsured patients also includes the administration fee. Medicare and commercial plans typically reimburse administration under a separate billing code, but cash-pay patients should ask the administering clinic to bundle or itemize those charges upfront.

Does Virginia Medicaid Cover Prolia?

Virginia Medicaid covers Prolia with prior authorization. The PA requirement generally means the prescribing physician must document that the patient meets specific clinical criteria before Medicaid approves reimbursement for the drug.

In practice, Virginia's Medicaid managed care organizations (MCOs), including Aetna Better Health of Virginia, Anthem HealthKeepers Plus, Molina Healthcare, and UnitedHealthcare Community Plan, each maintain their own preferred drug lists. Prolia appears on most of these formularies as a non-preferred or specialty-tier agent [2]. The typical PA criteria include:

• A confirmed diagnosis of osteoporosis (T-score of <-2.5 or fragility fracture history)
• Documentation of intolerance, contraindication, or inadequate response to at least one oral bisphosphonate (usually alendronate or risedronate)
• Prescriber attestation that the patient can adhere to the every-six-month injection schedule and follow-up monitoring

Virginia expanded Medicaid eligibility in 2019, so adults aged 19 to 64 earning up to 138% of the federal poverty level now qualify. Patients with osteoporosis who newly gained coverage under expansion and need Prolia should work with their prescriber to submit the PA promptly, since processing times range from 24 hours to two weeks depending on the MCO.

For dual-eligible patients (those enrolled in both Medicare and Medicaid), Medicare Part B is the primary payer for Prolia when administered in a medical setting, and Medicaid may cover the remaining cost-sharing. This arrangement can effectively reduce the patient's out-of-pocket expense to zero.

How Does Commercial Insurance Handle Prolia in Virginia?

Most commercial insurers in Virginia cover Prolia under the medical benefit (Part B equivalent) when administered in a provider's office, or under the pharmacy benefit when dispensed for self-injection. Step therapy is the standard gatekeeper. Plans typically require a trial of generic alendronate or risedronate before authorizing denosumab.

Anthem Blue Cross Blue Shield, the largest commercial insurer in Virginia, lists Prolia on its specialty tier. Patients with Anthem plans should expect a specialty copay ranging from $100 to $500 per injection before applying any manufacturer assistance. CareFirst BlueCross BlueShield, which covers parts of northern Virginia, follows a similar step-therapy protocol [3].

A 2023 analysis in the Journal of Managed Care & Specialty Pharmacy found that step-therapy requirements delayed denosumab initiation by an average of 4.2 months among commercially insured patients with documented bisphosphonate intolerance. For Virginia patients who have already failed or cannot tolerate oral bisphosphonates, providing documentation of that history at the time of the initial PA request can shorten the approval timeline significantly.

Employer-sponsored plans through large Virginia employers (including federal government employees using FEHB plans in the D.C. metro corridor) tend to have more favorable specialty drug coverage. FEHB plans such as Blue Cross Blue Shield FEP and GEHA often classify Prolia under the medical benefit with a 20% coinsurance after deductible, bringing the per-dose patient cost to roughly $300 before savings card application.

How the Amgen Prolia Savings Card Works in Virginia

Amgen offers the Prolia Complete savings card, which can reduce out-of-pocket costs to as little as $0 per dose for eligible commercially insured patients. The card is accepted at pharmacies and medical offices throughout Virginia.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Prolia. Government-insured patients, including those on Medicare, Medicaid, Tricare, or VA benefits, do not qualify for the savings card under federal anti-kickback regulations [4]. There is an annual benefit cap, which Amgen has set at $3,000 per calendar year in recent program cycles. Given that two doses per year at full copay could total $200 to $1,000 for most commercially insured patients, the $3,000 cap is sufficient for nearly all eligible users.

To activate the card, patients can enroll online through Amgen's Prolia Complete website or by calling the program's toll-free number. The card then functions as a secondary payer: the pharmacy or medical office bills the patient's primary insurance first, and the savings card covers all or part of the remaining copay or coinsurance.

One practical note for Virginia patients: if Prolia is billed under the medical benefit and administered in a physician's office, the office staff must process the savings card at the point of service. Some smaller practices in rural Virginia may be unfamiliar with buy-and-bill biologics savings programs. Patients should bring a physical or digital copy of their savings card to every injection appointment and confirm with front-desk staff before the injection that the card will be applied.

Is Compounded Denosumab Legal in Virginia?

Compounded denosumab is available in Virginia through licensed 503A compounding pharmacies. A 503A pharmacy operates under a patient-specific prescription and must comply with Virginia Board of Pharmacy regulations as well as the Federal Food, Drug, and Cosmetic Act section 503A.

There is a critical distinction here. Denosumab is a monoclonal antibody, and compounding a biologic is not the same as compounding a small-molecule drug like testosterone or progesterone. True biosimilar manufacturing requires FDA approval under the 351(k) pathway. What 503A pharmacies may legally do is compound denosumab from bulk pharmaceutical-grade ingredients for individual patients with valid prescriptions [5]. The FDA's guidance on compounding clarifies that 503A pharmacies cannot produce copies of commercially available biologics for general distribution.

Virginia-licensed 503A pharmacies that compound denosumab may offer it at substantially lower cost than brand-name Prolia. Some patients report out-of-pocket prices significantly below the $1,500 list price. Patients considering compounded denosumab should verify that the pharmacy holds an active Virginia Board of Pharmacy license and that the prescribing physician is comfortable monitoring treatment with a compounded product. Quality assurance, including potency testing and sterility verification, varies across compounding pharmacies, and patients should ask about these protocols before filling.

The Virginia Board of Pharmacy maintains a public search tool for verifying pharmacy licenses. Patients can confirm that a 503A facility is in good standing before obtaining compounded denosumab.

Can You Get Prolia via Telehealth in Virginia?

Virginia permits telehealth prescribing of Prolia. A licensed prescriber can evaluate a patient remotely, review bone density results and lab work, and write a prescription for denosumab without an in-person visit. Virginia's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person encounters [6].

The prescription itself can be sent to a specialty pharmacy for dispensing. The injection, though, still requires hands-on administration. Prolia is a subcutaneous injection given in the upper arm, thigh, or abdomen. While the technique is simpler than an intravenous infusion, the FDA-approved prescribing information specifies that Prolia should be administered by a healthcare professional.

For Virginia patients in rural areas (the southwest and Southside regions have fewer endocrinologists and rheumatologists per capita), telehealth consultations with specialists in Richmond, Charlottesville, or northern Virginia can bridge the access gap. The patient receives the prescription via telehealth and then visits a local primary care office or community health center for the actual injection every six months.

HealthRX offers telehealth evaluations for patients considering denosumab therapy. Virginia residents can consult with a licensed provider who can assess candidacy, order or review DEXA scans, check calcium and vitamin D levels, and prescribe Prolia if clinically indicated.

Prolia Discount Programs Available to Virginia Residents

Beyond the Amgen savings card, several additional discount avenues exist for Virginia patients who need help affording Prolia.

Amgen Safety Net Foundation. This is Amgen's patient assistance program (PAP) for uninsured or underinsured patients. Eligible individuals can receive Prolia at no cost. Income thresholds typically fall at or below 300% of the federal poverty level. The application requires documentation of income and insurance status and takes approximately four to six weeks to process [7].

State Pharmaceutical Assistance Programs (SPAPs). Virginia does not operate a standalone SPAP for osteoporosis drugs. Patients who are dual-eligible for Medicare and Medicaid, or who qualify for Medicare's Extra Help (Low-Income Subsidy), may have Prolia covered with minimal cost-sharing through their Part D or Part B plan.

GoodRx and RxAssist. Discount aggregators like GoodRx list Prolia coupons that may reduce the cash price at participating Virginia pharmacies by 10% to 25%. These discounts cannot be combined with insurance or the Amgen savings card. RxAssist maintains a database of patient assistance programs and can help Virginia patients identify all available options.

340B Drug Pricing Program. Virginia patients who receive care at 340B-eligible facilities, including federally qualified health centers (FQHCs) and certain hospital outpatient departments, may access Prolia at the 340B discounted price. Virginia has over 100 340B-covered entities, concentrated in underserved urban and rural areas [8]. The discount is passed to the facility rather than the patient directly, but 340B sites often reduce or waive patient cost-sharing on covered drugs.

What to Know Before Starting Prolia in Virginia

Prolia carries specific monitoring and discontinuation considerations that Virginia patients and prescribers should discuss before the first injection.

Calcium and vitamin D status must be adequate before initiating therapy. The Endocrine Society's 2024 clinical practice guideline recommends checking serum 25-hydroxyvitamin D and correcting deficiency (levels below 20 ng/mL) before the first Prolia dose [9]. Hypocalcemia is the most clinically significant risk, particularly in patients with renal impairment (eGFR <30 mL/min).

Discontinuation planning matters. The FREEDOM Extension study showed that patients who stopped denosumab after long-term use experienced rapid bone mineral density loss and a rebound increase in vertebral fracture risk within 12 to 18 months [10]. Current guidance from the American Association of Clinical Endocrinology recommends transitioning to a bisphosphonate (typically zoledronic acid 5 mg IV once or oral alendronate) after stopping denosumab to preserve bone density gains.

Virginia prescribers should also consider the patient's dental health. Osteonecrosis of the jaw (ONJ) is a rare but recognized adverse event, occurring in approximately 1 to 2 per 100,000 patient-years among osteoporosis patients on denosumab [1]. A dental examination before starting therapy is recommended by the American Dental Association, and Virginia patients with planned dental surgery should discuss timing with both their dentist and prescriber.

The standard dosing is 60 mg subcutaneously every six months. Missing a dose or delaying beyond six months increases fracture risk, so Virginia patients should set calendar reminders and coordinate with their administering provider to maintain the schedule.